News and Press Releases
Press releases
Theralase® Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
Press ReleaseToronto, Ontario – March 27, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
Press ReleaseToronto, Ontario – March 15, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Rutherrin® Technology Granted Allowance for Canadian Patent
Press ReleaseToronto, Ontario – March 7, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer
Press ReleaseToronto, Ontario – March 5, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Announces Settlement Agreement with Ontario Securities Commission
Press ReleaseToronto, Ontario – February 26, 2018 Theralase® Technologies Inc. (the “Company”) (TSXV: TLT) (OTCQX: TLTFF) announced today that the Company and Roger Dumoulin-White, former Chairman, President and Chief Executive Officer, have e...
Theralase® Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer
Press ReleaseToronto, Ontario – February 9, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light a...
Theralase® Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
Press ReleaseToronto, Ontario – January 18, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when...
Theralase® Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
Press ReleaseToronto, Ontario – January 17, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a biotech company focused on the commercialization of medical lasers to eliminate pain and the develop...
Theralase® Discovers Theralase® Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments
Press ReleaseToronto, Ontario – November 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Increases Revenue 12% for 3Q2017 Financial Statements
Press ReleaseToronto, Ontario – November 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and t...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
